Abstract

USE OF LOW MOLECULAR WEIGHT HEPARIN IN COVID-19 PATIENTS

Aishwarya Anand and Sajidul Hoque*

ABSTRACT

Introduction: Several of organ-specific and systemic phenotypes have been added by the COVID-19 pandemic, some previously identified in viral infections, including severe acute respiratory syndrome (SARS) and others that seem to be unique to SARS-coronavirus (CoV)-2. The Coronavirus disease 2019 (COVID-19) pathogenesis is increasingly being recognized where a high number of thrombotic episodes are being recorded which is supported by several coagulation markers. Hence, COVID-19 can be considered as a thrombosis risk factor and as a prothrombotic illness. Management recommendations such as the use of Heparin are driven by increasingly evolving information from scientific observations, autopsy-based results, and extrapolations from in-vitro and ex-vivo experiments and complex modeling; however, several issues remain unanswered and scientific trials that are needed to include proof in most fields have not been conducted. Objective: The following review summarizes emerging findings into pathobiology, mechanism(s), diagnosis, administration, scientific foundations, and proposed or continuing COVID-19-associated coagulopathy clinical trials and use of Heparin in COVID-19 patients. Conclusion: Use of thrombo-prophylactic i.e. Heparin, stratifying high-risk thrombosis patients, particularly the elderly, those with comorbidities and high D-Dimer levels is an important step to prevent thromboembolism in COVID-19 patients.

Keywords: COVID-19, thrombosis risk factor, use of Heparin.